Business Context and Reporting Period
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing peptide-based candidates for hematology, inflammatory, and immunomodulatory diseases. Its principal programs are rusfertide, PN-235, and PN-943. This unaudited Form 10-Q covers the three and nine months ended September 30, 2022, filed November 8, 2022.
The company has no approved products or product sales and operates as one reportable segment. Its primary near-term focus is rusfertide for polycythemia vera, while Janssen leads further development of PN-235 under the collaboration agreement.
Financial Metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| License and collaboration revenue | $0.0 million in 2022; $10.3 million in 2021 | $26.6 million in 2022; $18.7 million in 2021 |
| Research and development expense | $25.4 million; down 31% | $96.3 million; up 10% |
| General and administrative expense | $6.9 million; down 5% | $25.1 million; up 26% |
| Net loss | $31.2 million, or $0.64 per share | $93.2 million, or $1.90 per share |
| Net loss in prior-year period | $33.8 million, or $0.70 per share | $88.6 million, or $1.94 per share |
| Operating cash flow | Not separately provided | $(76.5) million |
| Stock-based compensation | $6.0 million | $18.7 million |
There is no meaningful traditional operating margin because the company has no product revenue and remains loss-making. Nine-month revenue benefited from a $25.0 million Janssen milestone received in April 2022 and recognized through completion of the collaboration performance obligation. No Janssen collaboration revenue was recognized in the third quarter because the performance obligation was completed as of June 30, 2022.
- Cash and cash equivalents at September 30, 2022: $152.8 million.
- Marketable securities: $114.6 million.
- Total cash, cash equivalents, and marketable securities: $267.4 million, compared with $326.9 million at December 31, 2021.
- Cash, cash equivalents, and restricted cash at September 30, 2022: $153.0 million.
- Accumulated deficit: $502.6 million.
- Total liabilities: $38.6 million, consisting primarily of operating lease liabilities, accounts payable, and accrued expenses.
- The filing reports no debt financing or material debt obligations; disclosed liabilities are primarily operating and trade obligations.
- Shares outstanding at October 31, 2022: 49.2 million.
Material Changes Versus the Prior Comparable Period
- Nine-month collaboration revenue increased $7.8 million, or 42%, to $26.6 million, primarily due to the Janssen milestone and related proportional revenue recognition. Third-quarter collaboration revenue fell to zero after completion of the performance obligation.
- Nine-month research and development expense increased $8.7 million, or 10%, driven by higher rusfertide clinical and manufacturing costs, higher PN-943 costs, and lower tax incentive reimbursements. The increase was partly offset by the absence of a $4.0 million Zealand-related milestone expense recorded in the prior-year quarter.
- Rusfertide research and development expense increased to $43.4 million for the first nine months, up $6.3 million, primarily due to the Phase 3 VERIFY trial.
- PN-943 expense increased to $33.6 million for the first nine months, but the program was subsequently deprioritized; only completion of the IDEAL trial extension was planned, while the company explored out-licensing.
- PN-235 and PN-232 expenses declined substantially following completion of Phase 1 activities, with Janssen advancing PN-235.
- Nine-month general and administrative expense increased $5.2 million, or 26%, mainly from personnel costs and higher stock-based compensation.
- Operating cash use improved from $80.9 million to $76.5 million, while financing cash inflows declined sharply from $127.8 million to $18.3 million because the prior-year period included a large public offering.
- The company raised $14.6 million net through its ATM facility in January 2022 and established a new $300.0 million Form S-3 registration statement, including a $100.0 million ATM facility. No securities had been sold under the new facility as of September 30, 2022.
Guidance, Outlook, Commentary, and Risks
- Management stated that existing cash, cash equivalents, and marketable securities were expected to fund anticipated operating and capital requirements for at least the next 12 months from the filing date. Management also expects cash burn to remain approximately at current levels for the remainder of 2022 and decrease in 2023.
- The company expects to require substantial additional financing to advance candidates through clinical development and potential commercialization. Additional equity, debt, or collaboration financing may be unavailable or may dilute existing stockholders or impose restrictive terms.
- VERIFY, a global Phase 3 rusfertide trial in polycythemia vera, was initiated in the first quarter of 2022. Site staff shortages and other operational challenges delayed recruitment; enrollment completion was expected in the second half of 2023.
- The FDA removed the rusfertide clinical hold in October 2021 after the company submitted safety information and proposed revised monitoring and stopping rules. The hold had followed benign and malignant skin tumors observed in a 26-week rasH2 mouse carcinogenicity study and a review of cancer cases in clinical trials.
- The FDA indicated an intent to rescind rusfertide’s Breakthrough Therapy designation in April 2022. The company voluntarily withdrew the designation in June 2022; Fast Track and orphan drug designations remained active.
- Janssen discontinued further development of PTG-200 and PN-232 in favor of PN-235. Janssen initiated the 240-patient FRONTIER 1 Phase 2b psoriasis trial and was expected to initiate a separate Phase 2 inflammatory bowel disease trial in 2023. The company remained eligible for approximately $855.0 million of future development and sales milestones, in addition to $112.5 million received.
- COVID-19, site staffing shortages, patient recruitment, supply-chain disruptions, inflation, interest rates, geopolitical instability, and the Russia-Ukraine conflict could delay trials or increase costs.
- The company remains dependent on third-party contract research organizations, manufacturers, and Janssen. Janssen may terminate the collaboration under specified terms, which could eliminate future milestones, royalties, and development support.
- The company has no approved products, product revenue, or sustained profitability and has never conducted a Phase 3 trial or submitted an NDA. Clinical, regulatory, manufacturing, reimbursement, intellectual-property, and commercialization risks remain substantial.
- The company reported no material legal proceedings and stated that disclosure controls and procedures were effective as of September 30, 2022.
Facts Investors Should Verify
- Whether VERIFY recruitment and the expected second-half 2023 enrollment completion remained on schedule.
- Updated clinical safety and efficacy data for rusfertide, including implications of the prior FDA clinical hold and tumor findings.
- Janssen’s continued development of PN-235, the timing of the planned inflammatory bowel disease trial, and the probability and timing of additional milestones.
- The company’s actual cash runway relative to its stated expectation of at least 12 months and the timing of any future capital raise.
- The extent to which deprioritization of PN-943 and other programs reduces spending without impairing potential licensing value.
- Potential dilution from the new $300.0 million Form S-3, the $100.0 million ATM facility, stock options, restricted stock units, and 2.75 million outstanding warrants.
- Effects of inflation, clinical supply constraints, site staffing shortages, and third-party manufacturing capacity on trial timelines and future cash requirements.